2The Serious Hazards of Transfusion Steering Group'. Serious hazards of transfusion: annual report 2006[ OL]. http://www, shotuk. org/SHOT report_2006, pdf.
3Amdt PA, Garratty G. A retrospective analysis of the value of monocytemonolayerassay results for predicting the clinical significance of blood group alloantibodies [ J ]. Transfusion, 2004,44 (9) :1273-1281.
4Chapman JF, Elliott C, Knowles SM, et al. Guidelines for compatibility procedures in blood transfusion laboratories [ J ]. Transfus ned,2004,14( 1 ) :59-73.
5Heddle NM, O Hoski P, Singer J, et al. A prospective study to determine the safety of omitting the antig~obulin erossmateh from pretransfusion testing [ J ]. Br J Haematol, 1992,81 (4) :579-584.
6Shulman IA, Nelson JM, Nakayama R. When should antibody screening tests be done for recently transfused patients [ J ]. Transfusion, 1990,30 ( 1 ) : 39-41.
8Sehonewille H,van de Watering LM, Loomans DS, et al. Red blood cell alloantibodies after transfusion : factors influencing incidence and specificity[J]. Transfusion,2006,46(2) :250-256.
9Kim HH,Park TS,Oh SH,et al. Delayed hemolytic transfusion reaction due to anti-Fy^b caused by a primary immune response: a case study and a review of the literature [ J ]. Immunohematol, 2004,20(3) :184-186.
10Takeuehi C, Ohto H, Miura S, et al. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red cell-reactive HLA antibodies [ J ]. Transfusion, 2005,45 ( 12 ) : 1925-1929.
